Systematic Evidence Map for Over One Hundred and Fifty Per- and Polyfluoroalkyl Substances (PFAS).


Journal

Environmental health perspectives
ISSN: 1552-9924
Titre abrégé: Environ Health Perspect
Pays: United States
ID NLM: 0330411

Informations de publication

Date de publication:
05 2022
Historique:
entrez: 17 5 2022
pubmed: 18 5 2022
medline: 20 5 2022
Statut: ppublish

Résumé

Per- and polyfluoroalkyl substances (PFAS) are a large class of synthetic (man-made) chemicals widely used in consumer products and industrial processes. Thousands of distinct PFAS exist in commerce. The 2019 U.S. Environmental Protection Agency (U.S. EPA) Per- and Polyfluoroalkyl Substances (PFAS) Action Plan outlines a multiprogram national research plan to address the challenge of PFAS. One component of this strategy involves the use of systematic evidence map (SEM) approaches to characterize the evidence base for hundreds of PFAS. SEM methods were used to summarize available epidemiological and animal bioassay evidence for a set of Systematic review methods were used to identify and screen literature using manual review and machine-learning software. The Populations, Exposures, Comparators, and Outcomes (PECO) criteria were kept broad to identify mammalian animal bioassay and epidemiological studies that could inform human hazard identification. A variety of supplemental content was also tracked, including information on More than 40,000 studies were identified from scientific databases. Screening processes identified 44 animal and 148 epidemiology studies from the peer-reviewed literature and 95 animal and 50 epidemiology studies from gray literature that met PECO criteria. Epidemiological evidence (available for 15 PFAS) mostly assessed the reproductive, endocrine, developmental, metabolic, cardiovascular, and immune systems. Animal evidence (available for 40 PFAS) commonly assessed effects in the reproductive, developmental, urinary, immunological, and hepatic systems. Overall, 45 PFAS had evidence across animal and epidemiology data streams. Many of the

Sections du résumé

BACKGROUND
Per- and polyfluoroalkyl substances (PFAS) are a large class of synthetic (man-made) chemicals widely used in consumer products and industrial processes. Thousands of distinct PFAS exist in commerce. The 2019 U.S. Environmental Protection Agency (U.S. EPA) Per- and Polyfluoroalkyl Substances (PFAS) Action Plan outlines a multiprogram national research plan to address the challenge of PFAS. One component of this strategy involves the use of systematic evidence map (SEM) approaches to characterize the evidence base for hundreds of PFAS.
OBJECTIVE
SEM methods were used to summarize available epidemiological and animal bioassay evidence for a set of
METHODS
Systematic review methods were used to identify and screen literature using manual review and machine-learning software. The Populations, Exposures, Comparators, and Outcomes (PECO) criteria were kept broad to identify mammalian animal bioassay and epidemiological studies that could inform human hazard identification. A variety of supplemental content was also tracked, including information on
RESULTS
More than 40,000 studies were identified from scientific databases. Screening processes identified 44 animal and 148 epidemiology studies from the peer-reviewed literature and 95 animal and 50 epidemiology studies from gray literature that met PECO criteria. Epidemiological evidence (available for 15 PFAS) mostly assessed the reproductive, endocrine, developmental, metabolic, cardiovascular, and immune systems. Animal evidence (available for 40 PFAS) commonly assessed effects in the reproductive, developmental, urinary, immunological, and hepatic systems. Overall, 45 PFAS had evidence across animal and epidemiology data streams.
DISCUSSION
Many of the

Identifiants

pubmed: 35580034
doi: 10.1289/EHP10343
pmc: PMC9113544
doi:

Substances chimiques

Fluorocarbons 0

Types de publication

Journal Article Review Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

56001

Subventions

Organisme : EPA
ID : 68HERC19D0003
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

BMC Med Res Methodol. 2011 Jun 17;11:92
pubmed: 21682870
J Am Med Inform Assoc. 2006 Mar-Apr;13(2):206-19
pubmed: 16357352
Syst Rev. 2016 Feb 10;5:28
pubmed: 26864942
Syst Rev. 2019 Jan 15;8(1):23
pubmed: 30646959
Int J Technol Assess Health Care. 2014 Jan;30(1):20-7
pubmed: 24451157
Environ Sci Technol. 2021 Dec 7;55(23):15575-15578
pubmed: 34751569
Syst Rev. 2016 May 23;5:87
pubmed: 27216467
Environ Health Perspect. 2021 Jul;129(7):76002
pubmed: 34251878
Environ Int. 2020 Aug;141:105736
pubmed: 32434117
Rev Environ Contam Toxicol. 2003;179:99-121
pubmed: 15366585
Toxicol Pathol. 2012 Oct;40(7):971-94
pubmed: 22723046
Environ Int. 2019 Sep;130:104871
pubmed: 31254867
Environ Health Perspect. 2019 Jan;127(1):14501
pubmed: 30632786
Environ Int. 2018 Dec;121(Pt 1):764-793
pubmed: 30336412
Environ Toxicol Chem. 2021 Mar;40(3):606-630
pubmed: 33017053
J Cheminform. 2017 Nov 28;9(1):61
pubmed: 29185060
Environ Int. 2020 Oct;143:105956
pubmed: 32702594
Environ Int. 2022 Sep;167:107408
pubmed: 35908389
Environ Int. 2019 Sep;130:104851
pubmed: 31284092
Environ Int. 2019 Sep;130:104884
pubmed: 31299560
Integr Environ Assess Manag. 2011 Oct;7(4):513-41
pubmed: 21793199
PLoS One. 2015 Jun 09;10(6):e0128591
pubmed: 26057616
Toxicology. 2021 Jun 15;457:152789
pubmed: 33887376
Ground Water. 2023 May-Jun;61(3):301-303
pubmed: 36807312
Toxicol Sci. 2020 May 1;175(1):35-49
pubmed: 32096866
Environ Int. 2020 May;138:105623
pubmed: 32203803
Syst Rev. 2015 Mar 14;4:26
pubmed: 25874967
J Expo Sci Environ Epidemiol. 2019 Mar;29(2):131-147
pubmed: 30470793
Environ Int. 2019 Apr;125:579-594
pubmed: 30591249

Auteurs

Laura M Carlson (LM)

Center for Public Health and Environmental Assessment, Health & Environmental Effects Assessment Division (HEEAD), U.S. Environmental Protection Agency (U.S. EPA), Durham, North Carolina, USA.

Michelle Angrish (M)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Durham, North Carolina, USA.

Avanti V Shirke (AV)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Washington, District of Columbia, USA.

Elizabeth G Radke (EG)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Washington, District of Columbia, USA.

Brittany Schulz (B)

Oak Ridge Associated Universities (ORAU), Oak Ridge, Tennessee, USA.

Andrew Kraft (A)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Washington, District of Columbia, USA.

Richard Judson (R)

Center for Computational Toxicology and Exposure (CCTE), U.S. EPA, Durham, North Carolina, USA.

Grace Patlewicz (G)

Center for Computational Toxicology and Exposure (CCTE), U.S. EPA, Durham, North Carolina, USA.

Robyn Blain (R)

ICF International, Fairfax, Virginia, USA.

Cynthia Lin (C)

ICF International, Fairfax, Virginia, USA.

Nicole Vetter (N)

ICF International, Fairfax, Virginia, USA.

Courtney Lemeris (C)

ICF International, Fairfax, Virginia, USA.

Pamela Hartman (P)

ICF International, Fairfax, Virginia, USA.

Heidi Hubbard (H)

ICF International, Fairfax, Virginia, USA.

Xabier Arzuaga (X)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Washington, District of Columbia, USA.

Allen Davis (A)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Washington, District of Columbia, USA.

Laura V Dishaw (LV)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Durham, North Carolina, USA.

Ingrid L Druwe (IL)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Durham, North Carolina, USA.

Hillary Hollinger (H)

Center for Public Health and Environmental Assessment, Health & Environmental Effects Assessment Division (HEEAD), U.S. Environmental Protection Agency (U.S. EPA), Durham, North Carolina, USA.

Ryan Jones (R)

Center for Public Health and Environmental Assessment, Health & Environmental Effects Assessment Division (HEEAD), U.S. Environmental Protection Agency (U.S. EPA), Durham, North Carolina, USA.

J Phillip Kaiser (JP)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Cincinnati, Ohio, USA.

Lucina Lizarraga (L)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Cincinnati, Ohio, USA.

Pamela D Noyes (PD)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Washington, District of Columbia, USA.

Michele Taylor (M)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Durham, North Carolina, USA.

Andrew J Shapiro (AJ)

Center for Public Health and Environmental Assessment, Health & Environmental Effects Assessment Division (HEEAD), U.S. Environmental Protection Agency (U.S. EPA), Durham, North Carolina, USA.

Antony J Williams (AJ)

Center for Computational Toxicology and Exposure (CCTE), U.S. EPA, Durham, North Carolina, USA.

Kristina A Thayer (KA)

Center for Public Health and Environmental Assessment, Chemical & Pollutant Assessment Division (CPAD), U.S. EPA, Durham, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH